Please login (Members) to view content or
(Nonmembers) this article.
Average: 5 (1 vote)

Chemotherapy Extravasation: Establishing a National Benchmark for Incidence Among Cancer Centers

Jeannette Jackson-Rose
Judith Del Monte
Adrienne Groman
Linda S. Dial
Leah Atwell
Judy Graham
Rosemary O’Neil Semler
Maryellen O’Sullivan
Lisa Truini-Pittman
Terri A. Cunningham
Lisa Roman-Fischetti
Eileen Costantinou
Chris Rimkus
Adrienne J. Banavage
Barbara Dietz
Carol J. Colussi
Kimberly Catania
Michelle Wasko
Kevin A. Schreffler
Colleen West
Mary Lou Siefert
Robert David Rice
CJON 2017, 21(4), 438-445 DOI: 10.1188/17.CJON.438-445

Background: Given the high-risk nature and nurse sensitivity of chemotherapy infusion and extravasation prevention, as well as the absence of an industry benchmark, a group of nurses studied oncology-specific nursing-sensitive indicators.

Objectives: The purpose was to establish a benchmark for the incidence of chemotherapy extravasation with vesicants, irritants, and irritants with vesicant potential.

Methods: Infusions with actual or suspected extravasations of vesicant and irritant chemotherapies were evaluated. Extravasation events were reviewed by type of agent, occurrence by drug category, route of administration, level of harm, follow-up, and patient referrals to surgical consultation.

Findings: A total of 739,812 infusions were evaluated, with 673 extravasation events identified. Incidence for all extravasation events was 0.09%.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or